Cohance Lifesciences share news, announcements and annual reports
NSE: COHANCEBSE: 543064Pharmaceuticals & BiotechnologySmall Cap
Cohance Lifesciences Limited · Formerly Suven Pharmaceuticals · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 2020
Last close ₹476.05down ₹3.20 (0.67%)BSE ₹476.80
Share price at the NSE close on 28 Oct 2026. Previous close ₹479.25.
28 Oct: open ₹484.00, high ₹487.40, low ₹471.70
52-week range of traded prices to 28 Oct 2026
₹266.70Low, 9 Mar 2026₹870.75High, 28 Oct 2025
- Next results date: the board meets on 6 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹18,214 Cr428th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 171.45
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹21 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 142.74
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.66
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 3.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹21 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 4.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.04
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,27,12243.3% delivered
Cohance Lifesciences disputes and clarifications
9 filed, newest first.
Jul 2026
Apr 2026
30 Apr · Legal
The exchange asked on 29 Apr 2026
12 Apr · Legal
The exchange asked on 10 Apr 2026
Jan 2026
19 Jan · Legal
Exchange has sought clarification from Cohance Lifesciences Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
Mar 2022
24 Mar · Legal
The exchange asked on 23 Mar 2022
Jul 2021
26 Jul · Legal
Exchange has sought clarification from Suven Pharmaceuticals Limited with respect to announcement dated 23-Jul-2021, regarding board meeting held on July 23, 2021. On basis of above the Company is required to clarify following: 1. Whether the incorporation would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being formed? If yes, nature of interest and details thereof and whether the same is done at "arm's length"; 2. Objects and effects of incorporation (including but not limited to, disclosure of reasons for incorporation of target entity, if its business is outside the main line of business of the listed entity); 3. Brief details of any governmental or regulatory approvals required for the incorporation; 4. Indicative time period for completion of the incorporation; 5. Nature of consideration - whether cash consideration or share swap and details of the same; The response of the Company is awaited.
Apr 2020
28 Apr · Legal
Exchange has sought clarification from Suven Pharmaceuticals Limited with respect to announcement dated 27-Apr-2020, regarding 'Intimation of Fire Incidence at Jeedimetla unit in Hyderabad'. On basis of above the Company is required to clarify following: 1. Expected quantum of loss/damage caused;2. Whether loss/damage covered by insurance or not including amount;3. Estimated impact on the production/operations in case of strikes/lock outs;The response of the Company is awaited.